

# Area Prescribing Group report

**APG meeting date:** Friday 02 February 2024 **Quorate:** Yes

The items in this report are supported by the area prescribing group and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

Document links provided for any APG recommendations are temporarily hosted on the legacy Pan Mersey APC website as a pragmatic solution until such time as a Cheshire and Merseyside APG website is available. The [legacy Cheshire formulary](#) will also be updated to reflect these changes.

CMAPG governance documents are now hosted on the new [Prescribing](#) section of the NHS Cheshire and Merseyside website, which is currently being developed

## New medicines NICE TAs

Proposal	Notes	Approval
<p><a href="#">Targeted-release budesonide for treating primary IgA nephropathy</a></p> <p><b>RAG designation:</b> Red</p> <p><b>APG subgroup:</b> 12 Jan 2024</p> <p><b>APG:</b> 02 Feb 2024</p>	<p><b>Date of NICE TA publication:</b> 20 Dec 2023</p> <p><b>Approval for implementation:</b> 90 days</p> <p><b>Deadline for implementation:</b> 19 Mar 2024</p> <p>Report in line with TA937. A Red RAG rating will be assigned in the formulary with a link to the NICE TA.</p> <p>In-tariff drug for specialist use only. This the first licensed treatment that specifically treats the condition, increasing the likelihood that people may avoid or delay the need for dialysis or a kidney transplant.</p>	<p><b>MOP:</b> 22<sup>nd</sup> February 2024, clinically supported by ICB Medicines Optimisation and Pharmacy Group.</p> <p>Approved by the ICB Medical Director 27<sup>th</sup> February 2024.</p>

Proposal	Notes	Approval
	<p>Costs are expected to be less than £8,800 per 100,000 population, which equates to £237,600 for the Cheshire and Merseyside population. NICE estimates that around 1,500 people will be eligible for treatment in England.</p>	
<p><a href="#">Dapagliflozin and empagliflozin for treating chronic kidney disease</a>  <a href="#">GP communication letter: SGLT2 inhibitors for chronic kidney disease (CKD)</a></p> <p><b>RAG designation:</b> Green  <b>APG subgroup:</b> 12 Jan 2024  <b>APG:</b> 02 Feb 2024</p>	<p><b>Date of NICE TA publication:</b> 20 Dec 2023  <b>Approval for implementation:</b> 90 days  <b>Deadline for implementation:</b> 19 Mar 2024</p> <p>Multi-prescribing statement in line with TA775 (dapagliflozin) and TA942 (empagliflozin). Dapagliflozin already has a green RAG in the legacy Cheshire and Merseyside formularies for CKD in line with TA775. A new green multiple prescribing statement was developed to include both drugs.</p> <p>APG raised a concern that SGLT2 inhibitors for CKD may be initiated by secondary care, or recommended by secondary care for primary care to prescribe. In order to prescribe safely, primary care prescribers require confirmation that the patient has been reviewed for suitability, counselled appropriately and that patient consent to treatment has been obtained. APG requested that a GP communication letter was produced to be used for this purpose, and that the prescriber checklist included in the SGLT2 inhibitor statement for use in heart failure was added to the CKD statement.</p> <p>NICE estimates that the cost (net resource impact) of implementing NICE TA942 in Cheshire and Merseyside is 0 in 2023/24, rising to £127,00 in 2024/25, £556,000 in 2025/26, 623,000 in 2026/27 and then £692,000 in 2026/27 when steady state is assumed to have been</p>	<p><b>MOP:</b> 22nd February 2024, clinically supported and approved by ICB Medicines Optimisation and Pharmacy Group.</p>

Proposal	Notes	Approval
	<p>reached. These costs take into account the potential resources released from delayed disease progression and includes both dapagliflozin and empagliflozin. Costs per 100,000 population are provided in the statement.</p>	
<p><a href="#">Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes</a></p> <p><b>RAG designation:</b> Red</p> <p><b>APG subgroup:</b> 12 Jan 2024</p> <p><b>APG:</b> 02 Feb 2024</p>	<p><b>Date of NICE TA publication:</b> 19 Dec 2023</p> <p><b>Approval for implementation:</b> 5 years</p> <p><b>Deadline for implementation:</b> 19 Dec 2028</p> <p>Statement in line with TA943.</p> <p>There is a phased implementation rollout period of 5 years for this TA due to capacity constraints and specialist training requirements.</p> <p>The NHS Supply Chain Framework is not yet available, therefore costs are based on an average annual cost for HCL systems of £5,684. This is likely to be an overestimate as substantial discounts for HCL systems are expected when the Framework is published.</p> <p>Based on an average annual cost for HCL systems as £5,684, and with NHS England funding for 75% incremental costs, costs are expected to be £845,000 in 2024/25, £862,547 in 2025/26, £1,057,224 in 2026/27, and £906,598 in year 2027/28.</p>	<p><b>MOP:</b> 22nd February 2024, clinically supported by ICB Medicines Optimisation and Pharmacy Group.</p> <p><b>(FIRC):</b> 12<sup>th</sup> March 2024, approved by ICB Finance, Investment and Resources Committee.</p>

## New medicines other

Proposal	Notes	Approval
<p><a href="#">Baricitinib for treating COVID-19</a>  <a href="#">Nirmatrelvir plus ritonavir, sotrovimab, and tocilizumab for treating COVID-19</a></p> <p><b>RAG designation:</b> Red  <b>APG subgroup:</b> 12 Jan 2024  <b>APG:</b> 02 Feb 2024</p>	<p>Minor update to include requirement for Blueteq form completion by the prescribing organisation for COVID-19 treatments.</p>	<p><b>MOP:</b> 22nd February 2024, clinically supported and approved by ICB Medicines Optimisation and Pharmacy Group.</p>

## APG reports

Title	Notes	Approval
<p><a href="#">NICE TA adherence checklist</a>  December 2023</p>	<p>For noting.</p>	<p><b>MOP:</b> 22nd February 2024, noted by ICB Medicines Optimisation and Pharmacy Group.</p>